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Objective. Cannabis use predicts psychosis in longitudinal studies, but it is difficult to infer causation. Some precursor variables
predict both, including childhood trauma and adversity. Additionally, some of the desired effects of cannabis use resemble the
symptoms of psychosis. It would be preferable to assess psychotomimetic or “unusual” experiences that include psychotic
symptoms but without assuming pathology. Finally, it is possible that similar people are prone to psychosis and drawn to cannabis
use, perhaps, because they are sensitive or attracted to unusual experiences. Schizotypy provides a trait measure of proneness to
unusual experiences. +e study aimed to examine cross-sectionally relationships between cannabis use, schizotypy, and unusual
experiences whilst controlling for current trauma symptoms. Method. A volunteer online sample (n� 129, 64% women, pre-
dominantly students) who had used cannabis at least once was recruited. People who reported active effects of past trauma were
excluded with a brief primary care posttraumatic stress disorder screen. Participants completed the Oxford-Liverpool Inventory of
Feelings and Experience, the Cognitive Failures Questionnaire, and measures of substance use and sociodemographics. Results.
+e majority of respondents recounted unusual experiences after cannabis use, and many of these might have been considered
symptoms of psychosis if they had received medical attention. In regression analysis, the only predictor of the unusual experiences
scale of O-LIFE was schizotypy (measured by the remaining subscales; 4% of variance). +ere were no correlations between
cannabis use frequency and schizotypy or unusual experiences. Conclusions. +ese findings suggest that, after controlling for
schizotypy and excluding people who are actively experiencing the effects of past trauma, frequency of cannabis use does not
predict unusual experiences. However, individuals with schizotypal personality traits may have more unusual experiences when
using cannabis.
1. Introduction
Whether personality or predisposition mediate the rela-
tionship between cannabis use and psychosis is an important
question because psychosis is amongst the gravest possible
risks of cannabis use and there were approximately 192
million cannabis users globally in 2016 [1]. In England and
Wales in 2017/2018, about 6% of 16- to 59-year-olds re-
ported cannabis use within the last year [2]. Cannabis can
cause transient psychosis-like experiences [3–5], including
thought disorder, paranoia, delusions, slowing of time,
disturbances in visual perception, visual hallucinations,
disturbances in body perception, depersonalization, and
changes in mood. +ese are called “unusual,” “psychoto-
genic,” or “psychotomimetic” experiences and can resemble
psychosis [6].
However, it is long known that the effects usually wear
off harmlessly [3]. Indeed, some of the psychotomimetic
effects are amongst the effects that users seek [7]. A few users
become acutely distressed and seek medical help [8, 9]. Most
frequent symptoms are paranoia with or without delusions.
Treatment generally consists of reassurance and waiting for
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the effects to wear off. A complication in understanding the
psychotomimetic effects of cannabis is that its constituents
and their metabolites have long half-lives and some are
stored in body fat [10]. Consequently, psychotomimetic
effects experienced hours, or even days, after subjective
intoxication has ended may still be caused by cannabis.
Furthermore, intermittent use might sensitize the user to
psychotomimetic experiences even in between bouts of use.
Indeed, of greater concern is that cannabis may have
enduring psychotomimetic effects. Structural equation
modelling within one large longitudinal study suggested that
cannabis use plays a causal role in the development of
psychotic symptoms in individuals who are genetically
vulnerable [11]. A meta-analysis of longitudinal studies of
cannabis use and subsequent psychotic symptoms or
schizophrenia found an odds ratio of 3.90 (95% CI: 2.84 to
5.34) for the risk of psychosis outcomes for the heaviest of
cannabis users in comparison with nonusers [12]. Another
meta-analysis found evidence for a relationship between
cannabis use and earlier age of onset of psychosis [13].
Moreover, onset of cannabis use before the age of 16 may
increase the risk of psychosis fourfold by the age of 26 [14].
However, there is a problem of confounding variables [15].
Major confounds include adverse childhood experiences
[16, 17] and schizotypy, which is also correlated with
childhood trauma [18].
Schizotypy is a cluster of general population personality
traits derived from psychosis symptomology, positive
symptoms, negative symptoms, and disorganization [19, 20].
It can be linked to a pattern of general personality using five-
factor personality measures [21] and its traits mirror the
three-factor model of schizophrenia [22]. Schizotypy scores
are moderately stable over time [23], so a high score for
schizotypy is unlikely to be caused entirely by cannabis use.
Current cannabis users score more highly for schizotypal
personality characteristics than nonusers and past users [24],
and regular users score higher on schizotypy than less-
regular users [25]. Furthermore, people with schizotypal
traits tend to be more likely to experience unusual experi-
ences following cannabis use [26]; both psychosis and
schizotypy levels increase with cannabis usage in a dose-
dependent manner [27] and psychotogenic symptoms after
cannabis use are predicted by high schizotypy scores
[26, 28].
However, some unusual experiences, including intru-
sions, hallucinations, and depersonalization, are also known
symptoms of posttraumatic stress disorder (PTSD) and
acute stress disorder [29], which may reflect positive psy-
chotogenic symptomology. A strong relationship has been
reported between schizotypal personality characteristics and
trauma [30], while lifetime prevalence of cannabis use is
higher amongst people with PTSD diagnoses [31].+erefore,
in interpreting findings, it is essential to be aware of these
complications.
Another difficulty with the previous literature is that the
measurement of “psychosis” has been inconsistent, with the
use of several different questionnaires, including measures
designed for clinical populations rather than the general
population [19] and specially developed measures for the
psychosis-like effects of cannabis [25]. Many of these
measures were developed on the assumption that unusual
experiences are either precursors of psychosis or undiag-
nosed psychotic symptoms. However, this assumption has
been challenged on the basis that occasional psychotogenic
experiences are not unusual in the general population and do
not necessarily cause distress [32, 33]. Consequently, efforts
have been devoted to developing questionnaires about such
experiences that do not assume pathology but rather focus
on a personality approach [19]. One leading and valid
measure is the Oxford-Liverpool Inventory of Feelings and
Experience (O-LIFE), which was designed for nonclinical
samples [34].
+e present study’s aim is to examine the relationship
between cannabis use and unusual experiences, controlling
for schizotypy using the relevant subscale O-LIFE and ex-
cluding participants who exhibited current symptoms of
PTSD [35]. It also asked participants to provide an example
of an unusual experience they had had whilst using cannabis
on their own, with the aim of better understanding the
content of unusual experiences.
2. Method
2.1. Participants. Opportunistic anonymous volunteer
sampling online was utilized by using targeted posts on
social media websites (n� 180; 65 males and 115 females;
mean age� 26.00, SD� 9.80). Inclusion required cannabis
use at least once. Excluded were participants with high PTSD
scores. +e study aimed to recruit only participants aged 18
or older, but two participants recorded their age as 17. As the
age of consent for research in the UK is 16, it was decided to
retain these participants for the analysis.
2.2. Design. A correlational design was employed, plus a
single qualitative question about an unusual experience
whilst using cannabis. +e variable to be predicted was the
unusual experiences score. +e predictor variables were age,
cognitive impairment, ethnicity, education level, gender,
household income, frequency of cannabis use, occupation
status, other drug use, purpose of cannabis use, and
schizotypal personality traits.
2.3. Materials. +e questionnaire was presented online to
allow for easy circulation, reach a larger population, and
facilitate anonymity [36]. It began with an information sheet
that explained the nature of the study, followed by a consent
page with check box choices. It then comprised seven main
sections: 1. Primary Care PTSD Screen (PC-PTSD) [37],
which is using a cutoff of 3+ as the criterion for exclusion. 2.
Demographics: age, gender, ethnicity, education level, oc-
cupation status, and household income based on UK tax
bands [38]. 3. Cannabis use: once inmy life, occasional use (a
few times across my life), yearly (I use it at least once every
year), monthly (I use it nearly every month), Weekly (I use it
nearly every week), or frequent (I use it nearly every day). 4.
Unusual experiences subscale from O-LIFE: this subscale
has internal consistency (Cronbach’s α� 0.89) [39] plus a
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qualitative, free text question asking for a description of one
unusual experience following cannabis use. 5. Other drug
use: list of 20 drugs, participants ticked each they had used,
giving a score out of 20. A similar question asked about
drugs used with cannabis. 6. Schizotypy using the other
sections of O-LIFE; cognitive disorganization, introverted
anhedonia, and impulsive nonconformity. All have internal
reliability [39]—cognitive disorganization (Cronbach’s
α� 0.87), introvertive anhedonia (Cronbach’s α� 0.82), and
impulsive nonconformity (Cronbach’s α� 0.77). 7. Cogni-
tive Failures Questionnaire (CFQ) [40], which has strong
internal reliability (Cronbach’s α� 0.93) [41]. +e complete
questionnaire is available in Supplementary Materials.
2.4. Ethical Approval. +e study was approved by the
University Faculty Ethics Committee, which accords with
the Declaration of Helsinki. Participation was by informed
consent, and the survey was anonymous except for IP ad-
dresses that were deleted as the data were downloaded.
Information and contact details for organizations, including
Samaritans and Talk To Frank, were provided to participants
in order for them to seek advice or help regarding what they
expressed within the questionnaire and more specifically
drugs and drug use. Participants were also provided with
contact details for the researcher, the research supervisor,
and the University’s ethics committee should they need
them.
3. Results
3.1. Statistical Analysis. PC-PTSD scores showed 52 par-
ticipants (33 females and 19 males; age M� 27.25,
SD� 12.52) scoring 3+ on the trauma screening measure,
who were excluded. +ose excluded did not differ signifi-
cantly on any demographic or epidemiological variables, or
on substance use. Using G∗ Power 3.1, the final sample size
of 129 gave power of 0.90 to detect a small effect size (0.1) in
the regression analysis reported below.
Of those included, 36% were male, and 64%, female.
Mean age was 25.41 (SD� 8.47). All but 5 were white; 68%
were educated to university level, 26% to college level, and
only 5% less than that; 62.79% were in education (59.6%
university, 3.10% college); 33% were working; and only 4%
were unemployed. Household income was low for 26%,
average for 59%, and high for 16%, based on the UK Tax
Band criteria [38]. +us, it was a youthful, relatively highly
educated, and high-social-status sample, with women over-
represented compared with typical samples of drug users.
Table 1 shows the frequency of cannabis use.
+e Unusual Experiences subscale was reliable
(α� 0.90).+emean number of types of unusual experiences
was 7.2 (SD� 6.2), and the range was from 0 to 28 types of
experience. +e other three subscales of the O-LIFE com-
bined to measure schizotypy was also reliable (α� 0.89), as
was the CFQ (α� 0.90).
Aside from the CFQ, all other continuous variables were
not normally distributed (Shapiro–Wilk p< 0.05); hence,
nonparametric testing was undertaken. Table 2 shows the
correlations between unusual experiences, schizotypy, fre-
quency of cannabis use, and the other variables. As shown in
Table 2, unusual experiences correlated with schizotypy and
cognitive impairment, while schizotypy was also correlated
with cognitive impairment and age. Cannabis use was not
correlated with either schizotypy or unusual experiences but
was with other drug use and using other drugs simulta-
neously with cannabis.
Of gender, ethnicity, occupation, household income, and
purpose of use, only the education level was associated with
the frequency of cannabis use (Fisher’s exact test, p � 0.010).
As the data did not meet the assumption of normality,
nonparametric independent-sample Kruskal–Wallis tests
were undertaken, examining differences in key variables
across different categories. Schizotypy (H [2]� 19.34,
p< 0.001) differed across education levels. Post hoc tests
indicated that there was a significant difference in schizotypy
scores between individuals with university education and
college education (p< 0.001). Schizotypy did not differ
across the other variables mentioned above or by frequency
of cannabis use. Unusual experiences did not differ across
any category.
Prior to conducting a multiple regression analysis, the
assumptions for this statistical analysis were tested. Due to
the data not meeting the assumption of normal distribution,
the continuous variables were transformed logarithmically
before being entered into a regression analysis. Following
this, the data met all assumptions for a regression analysis to
avoid type I and type II errors [42]. +e variables possessed
nonzero variance, were lacking in autocorrelation (Durbin
Watson� 2.03), and displayed linearity within scatterplots,
and the residuals displayed sufficient normal distribution
within the P–P plot for the model. Moreover, the analysis of
collinearity statistics suggests that the assumption of non-
multicollinearity was met, with all VIF scores well below 10
and all tolerance scores were above 0.2. +e assumption of
homoscedasticity was met as evidenced by the plot of
standardized residuals versus standardized predictor values,
showing no obvious signs of funnelling. Finally, Cook’s
distance values were all under 1, suggesting that there were
not any individual cases biasing the model.
As shown in Table 3, a multiple regression analysis was
conducted with unusual experiences scores as the outcome
variable. Initially, control variables were entered stepwise
into the first block: age, gender, ethnicity, education level,
occupation status, and household income. Into the second
block, the following variables were entered stepwise: O-LIFE
score, CTQ score, purpose of cannabis use, number of other
Table 1: Frequency of cannabis use within the sample of 129
participants.
Frequency N %
Once in their lifetime 10 7.75
Occasional use across their lifetime 41 31.78
At least once a year 12 9.30
At least once a month 26 20.16
At least once a week 16 12.40
Frequently (nearly every day) 24 18.60
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drugs used, and number of other drugs used with cannabis.
In the final block, frequency of cannabis use was entered.
Only schizotypy was predictive of the unusual experi-
ences score, (F (1, 111)� 4.53, p � 0.034; R2 � 0.040). No
other variables added significant variance. Because schizo-
typy may be a risk factor for unusual experiences after
cannabis, Spearman’s rho was calculated correlating schiz-
otypy and unusual experiences separately for frequent users
of cannabis (at least once a week; rs � 0.48) and those who
used less often (rs � 0.23). +e correlation for the entire
sample was rs � 0.31. While there is no formal way of de-
fining when one correlation is significantly larger than
another, the relationship between schizotypy and unusual
experiences appeared to be intensified amongst frequent
users. Looking at the scatterplot, 7 participants scored >20
on unusual experiences of whom 4/7 were occasional users,
1/7 was a yearly user, and 2/7 were frequent users.
3.2. Unusual Experiences following Cannabis Use. Two
overarching themes emerged from the qualitative responses
to the question, “Please describe one instance of an unusual
experience following cannabis use in isolation/on its own?”-
—symptoms of cannabis intoxication (DSM-5 criteria; [29],
n� 51) and psychotogenic experiences (n� 99). Twenty-six
respondents did not report any unusual experiences fol-
lowing cannabis use, so they were excluded, as were 3 who
reported never using cannabis by itself. Another 8 responses
were excluded for not providing a coherent and relevant
description. Responses categorized as “cannabis intoxica-
tion” are not discussed further here, and they included
intense hunger, impaired motor coordination, tachycardia,
anxiety, sensation of slowed time, and euphoria.
3.3. Psychotogenic Experiences. “Psychotogenic experiences”
included paranoia/fear, hallucinations, delusions, deper-
sonalization/derealization, perceptual abnormalities, mem-
ory, and relapse. Some responses were categorized into
multiple themes. Figure 1 depicts the distribution of re-
sponses between the subthemes, which are detailed below.
No participants reported that these experiences persisted
beyond the period of cannabis intoxication.
3.3.1. Paranoia/Fear
(a) Without explanation (n� 10): “the feeling of dread
and imminent danger with no good reason” and
“heart palpitations and extreme terror.”
(b) With explanation (n� 6): “standing in my boyfriends
[sic] kitchen a door shook and I thought it was a
ghost” and “I thought people were outside my window,
but it was a cow mooing.”
(c) Persecutory delusion (n� 1): please see below under
Section 4.3.3(b).
3.3.2. Hallucinations
(a) Visual hallucinations (n� 10): “the person I was
talking to turned into a blue fuzzy number 2” and
“seeing shadows in the corner of a room as a person,
Table 2: Spearman’s rho correlation coefficients between the ordinal variables within the study.
Schizotypy Cannabis use frequency Cognitiveimpairment Other drugs Other drugs with cannabis Age
Unusual experiences ∗∗0.31 0.03 ∗∗0.23 −0.06 0.15 −0.12
Schizotypy −0.08 ∗∗0.55 −0.12 0.03 ∗∗−0.39
Cannabis use frequency −0.02 ∗∗0.44 ∗∗0.57 −0.14
∗∗p< 0.01 level (two-tailed).
Table 3: Summary of the stepwise regression analysis for variables predicting unusual experiences.
B β p
Model 1
Constant 0.37 (−0.81, 1.55) 0.534
Schizotypy 0.40 (0.03, 0.76) 0.20 0.034
Excluded variables T p




Education level 0.56 0.577
Occupation status −0.15 0.878
Household income −0.85 0.399
Purpose of cannabis use 0.43 0.672
Number of other drugs used 0.43 0.521
Number of other drugs used with cannabis 0.64 0.530
Cognitive impairment −0.12 0.901
95% confidence intervals are reported in parentheses. Statistics for the excluded variables can also be seen within the table.
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even though the details of the person were imagined
beyond the details created by the shadows.”
(b) Auditory hallucinations (n� 5): “I could hear people
in the eaves of my room.” Another could hear a “cat
meowing to be let in,” but there was no animal there.
(c) Tactile hallucinations (n� 2): “felt like a hand
reached up my back and grabbed my head” and “felt
like an army of ants was crawling over my skin.”
(d)Olfactory and gustatory hallucinations (n� 2):
gustatory “water tasted like wine” and olfactory
“overwhelmingly strong smell of freshly baked bread,
even though I was in a field with no bread around.”
3.3.3. Delusions
(a) Grandiose delusions (n� 7): “I thought I could
control the clouds with my eyes” and “feeling more
intelligent than usual, specifically believing I could
understand human interactions in terms of atomic
level movements.”
(b) Persecutory delusions (n� 4): “I was 100% sure I was
about to get mugged by a guy on a motorbike” and
“could not get the sounds of sirens out of my head.
Had the constant belief that the police were going to
get me.”
(c) Spiritual delusions (n� 2): “the presence of God” and
contact with God “I was told to by Allah himself.”
3.3.4. Depersonalization/Derealization
(a) Depersonalization (n� 26): +e most common
psychotogenic experience is, “My arms went numb
and did not feel my own even when waving them” and
“I felt like my mind had left my body.” An example of
depersonalization related to mental processes is, “I
found it impossible to express words and instead could
only begin to spell them out letter by letter.”
(b) Derealization (n� 10): “almost feeling as if I’m in a
bubble that surrounds me and I’m not quite in the
outer world” and “I feel like my head goes real [sic] big
and small really fast.”
3.3.5. Perceptual Abnormalities
(a) Visual (n� 9): “several inanimate objects in my room
(drying rack, posters) looked like figures/people” and
“feeling as though objects (e.g., a table, a bottle on the
table) were very far away even though they were right
in front of me.”
(b) Auditory (n� 4): “I was once listening to a song and
thought it was still playing for the next 2 hours when it
had stopped after one play” and “hearing people talk
to you really loud but there [sic] just talking
normally.”
(c) Strange self-perception (n� 7): “I once felt alarm-
ingly aware of my bones/skeletal structure and my
muscles moving my frame” and “. . .like my head was
separate to my body and felt a lot warmer than the
rest of my body.”
(d) Lucid dreaming (N� 2): “I experience events that feel
very real” and “I used to vividly see an image for a split
second, followed by it melting away.”
3.3.6. Memory
(a) Memory failures (n� 3): “it is hard to recall a specific
incident (partly down to the effect of cannabis [sic] on
my memory!)” and “I think I’ve said things and
started conversations when I haven’t.”
(b) Reminiscence (n� 1): “A random picture or song can
transfer me back to the exact location and time it
happened and make me think the same as I did back
then also causes me to have the same emotions.”
3.3.7. Relapse (N� 1). “I have had more psychotic experi-
ences, made worse by cannabis use.”
Participants reported a wide variety of psychotogenic
experiences whilst taking cannabis, which included some
quite extreme delusions, hallucinations, and other distor-
tions of perception and cognition. +ese experiences in-
cluded many that would have met criteria for psychosis, if
they had not been associated with cannabis use.
4. Discussion
By measuring unusual experiences rather than psychotic
symptoms and excluding people who may have been cur-
rently experiencing trauma symptoms, this study found that
schizotypy modestly predicted unusual experiences (4% of
variance) and frequency of cannabis use did not add any
additional variance. +is is different from previous studies
using measures of psychosis [26, 27].
In a cross-sectional study, it is impossible to tell how
cannabis use may have affected schizotypy. Nonetheless,
within the design of the regression analysis, schizotypy was a
better predictor of unusual experiences than cannabis use.
At minimum, this suggests that controlling for schizotypy
eliminates the effects of cannabis use on the prevalence of
unusual experiences amongst people who are not currently



















Figure 1: A diagram depicting the subthemes extracted from the
analysis, where N is the number of responses.
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variables included were predictive of unusual experiences,
although schizotypy varied with educational levels and more
frequent cannabis users tended to use other drugs more.
+ere was some evidence that the relationship between
schizotypy and unusual experiences was larger amongst
frequent cannabis users, as reported previously [26, 27], but
this relationship needs further research, ideally longitudinal.
+e implication is that cannabis use makes unusual expe-
riences more likely but primarily for people already prone to
unusual experiences.
It is worth noting that in this volunteer nonclinical
sample, there were no significant gender differences in
substance use, schizotypy, or unusual experiences. +is is
unusual in mental health and addiction research; often men
use substances more heavily and are more prone to psy-
chosis. It seems probable that the low entry criteria of having
used cannabis at least once helped to equalize the usual
gender difference, as indicated by the fact that nearly 2/3 of
the sample was women. Results from this relatively light
cannabis-using, predominantly female sample cannot
readily be generalized to heavier cannabis-using or clinical
populations.
Participants reported a wide range of psychotomimetic
experiences whilst taking cannabis, and only 12% were
unable to report such an experience. Many of these might
have been judged to be psychotic symptoms should they
have been presented to a health care professional without
mentioning cannabis use. +e DSM-5 acknowledges that
perceptual abnormalities can occur as part of cannabis in-
toxication [29]. However, from what was reported here,
these experiences can be quite strange and intense and there
is a need to raise awareness of this amongst both users and
clinicians. +is is particularly important for people who
score highly on schizotypy, as they may be more vulnerable
to unusual experiences. With hindsight, it would have been
of interest to ask also about the duration of these experiences
and any distress caused, for affective content and inter-
pretation may mediate the relationship between unusual
experiences and psychosis [40, 41]. Moreover, in future
research, it would be of interest to relate the nature and
content of unusual experiences to schizotypy.
+is study was cross-sectional, consisting of modest
sample size, and a volunteer sampling method was used.
Nonetheless, its findings suggest that, even if the lack of a
cannabis-unusual experiences relationship after controlling
for schizotypy does not replicate, studies of cannabis and
psychotomimetic experiences (or psychotic symptoms)
should consider schizotypy as well. +e established rela-
tionship between cannabis use and psychotic symptoms is
complicated by personality, by any enduring effects of past
trauma, and by how participants choose to manage their
cannabis use based on what experiences they have had with
it. +ese factors need to be considered carefully in future
research.
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